Statements (108)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Ti_Genix
gptkb:Ti_Genix_NV |
| gptkbp:activities |
gptkb:drug
immunomodulatory effects promotes tissue regeneration |
| gptkbp:appointed_by |
injection
|
| gptkbp:clinical_trial |
gptkb:Celyad
gptkb:government_agency gptkb:2015 gptkb:Belgium gptkb:Monarch gptkb:Spain gptkb:United_Kingdom ongoing Phase III overall response rate overall survival progression-free survival Phase 1/2 pending publication positive outcomes reported clinicaltrials.gov primary and secondary endpoints defined C-005 study completed Phase II and III trials multiple sites across Europe required prior to treatment |
| gptkbp:collaborations |
academic institutions
multiple clinical research organizations |
| gptkbp:collection |
ongoing
|
| gptkbp:committee |
established
|
| gptkbp:competitors |
other CART-cell therapies
|
| gptkbp:developed_by |
gptkb:Celyad
gptkb:Ti_Genix |
| gptkbp:dosage_form |
varies by trial
single administration |
| gptkbp:duration |
varies by patient
varies by trial |
| gptkbp:events |
monitoring for fistula closure
|
| gptkbp:feedback |
varies
generally positive |
| gptkbp:formulation |
sterile injectable suspension
|
| gptkbp:frequency |
single dose
|
| gptkbp:future_plans |
ongoing trials
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cx601
|
| gptkbp:invention |
patented technology
patents filed |
| gptkbp:investment |
high
|
| gptkbp:is_a_source_of |
autologous T-cells
human adipose tissue |
| gptkbp:is_effective_against |
under investigation
improves healing of fistulas |
| gptkbp:is_monitored_by |
required during trials
regular follow-ups required |
| gptkbp:is_used_for |
treatment of acute myeloid leukemia
complex perianal fistulas |
| gptkbp:launch_date |
gptkb:2018
|
| gptkbp:manager |
intravenous
|
| gptkbp:market |
ongoing monitoring for safety
|
| gptkbp:marketed_as |
Alofisel
available in select European countries |
| gptkbp:moral |
obtained for trials
|
| gptkbp:origin |
gptkb:Europe
|
| gptkbp:outcome |
under investigation
|
| gptkbp:partnerships |
biotech companies
|
| gptkbp:population |
adult patients
|
| gptkbp:produced_by |
complex and regulated
|
| gptkbp:production_company |
gptkb:Celyad_Oncology
|
| gptkbp:products |
approved in the US for trials
|
| gptkbp:provides_information_on |
outpatient
recommended for specific cases |
| gptkbp:publishes |
peer-reviewed journals
multiple peer-reviewed articles |
| gptkbp:receives_funding_from |
public and private investment
public and private grants grants and investments |
| gptkbp:recruitment |
based on medical history
|
| gptkbp:regulatory_body |
gptkb:European_Medicines_Agency
|
| gptkbp:regulatory_compliance |
gptkb:European_Medicines_Agency
investigational not yet approved |
| gptkbp:research |
conducted
|
| gptkbp:research_areas |
hematology
gastroenterology |
| gptkbp:research_focus |
oncology
|
| gptkbp:safety_features |
under investigation
generally well tolerated |
| gptkbp:scholarships |
gptkb:stock_market_index
|
| gptkbp:side_effect |
under investigation
injection site reactions |
| gptkbp:status |
ongoing studies
|
| gptkbp:student_enrollment |
specific criteria
adults with complex perianal fistulas |
| gptkbp:supply_chain |
managed by Ti Genix
|
| gptkbp:target_audience |
patients with Crohn's disease
|
| gptkbp:targets |
B-cell malignancies
C D19 positive cells |
| gptkbp:training |
required for administration
|
| gptkbp:treatment |
gptkb:hospital
gptkb:vaccine remission assessed through clinical evaluations fistula closure reduction in fistula drainage |
| gptkbp:type_of |
allogeneic adipose-derived stem cells
|
| gptkbp:type_of_insurance |
varies by region
|